Avacta Group plc
("Avacta" or "the Group" or "the Company")
Block Listing Six Monthly Return
LONDON AND PHILADELPHIA - October 27, 2025 Avacta Therapeutics (AIM: AVCT, 'the Company'), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
|
Name of applicant: |
Avacta Group plc |
|||
|
Name of scheme: |
EMI scheme |
|||
|
Period of return: |
From: |
28 April 2025 |
27 October 2025 |
|
|
Balance of unallotted securities under scheme(s) from previous return: |
228,380 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
nil |
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
103,822 |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
124,558 |
|||
|
Name of applicant: |
Avacta Group plc |
||||
|
Name of scheme: |
LTIP/ESOS scheme |
||||
|
Period of return: |
From: |
28 April 2025 |
27 October 2025 |
||
|
Balance of unallotted securities under scheme(s): |
1,546,375 |
||||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
6,500,000 |
||||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
6,862,713 |
||||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
1,183,662 |
||||
|
Name of contact: |
Brian Hahn, Company Secretary |
||||
|
Telephone number of contact: |
+ 44 (0) 1904 217070 |
||||
Ends-
For further information from Avacta Group plc, please contact:
|
Avacta Group plc Christina Coughlin, Chief Executive Officer |
via ICR Healthcare |
|
Peel Hunt (Nomad and Joint Broker) James Steel / Chris Golden |
|
|
Panmure Liberum (Joint Broker) Emma Earl / Will Goode / Mark Rogers Zeus (Joint Broker) James Hornigold / George Duxberry Dominic King |
|
|
ICR Healthcare (Europe/UK media and investors) Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert |
|
|
Investor Contact Renee Leck THRUST Strategic Communications |
|
|
Media Contact Carly Scaduto THRUST Strategic Communications |
About pre|CISION®
The key aspect of pre|CISION® is its peptide drug conjugates (PDC) technology. The combination of the cancer drug and the proprietary cleavable peptide (the PDC) is inert and incapable of entering cells and killing them until the peptide is specifically released within the tumor. The active payload in the pre|CISION® PDC is released when the PDC comes into contact with the common tumor-associated protein, known as fibroblast activation protein (FAP), in the tumor. The release of the payload from the pre|CISION® product directly in the tumor results in higher concentration of the drug at the tumor and lower blood and healthy tissue levels than standard systemic administration, offering the potential to improve efficacy and patient tolerability.
About Avacta - www.avacta.com
Avacta is a clinical stage life sciences company developing an innovative proprietary drug delivery peptide drug conjugate (PDC) platform, pre|CISION®. The pre|CISION® platform uniquely enables the repurposing of a range of oncology drugs as PDC payloads with the goal to significantly reduce toxicity and side effects for patients by concentrating the drug directly in the tumor.